Abbott files extended-release gabapentin in US for post-herpetic pain
This article was originally published in Scrip
Executive Summary
Abbott has filed its extended-release once-daily tablet gabapentin formulation, DM-1796, with the US FDA for the treatment of postherpetic neuralgia (PHN).